$heff thanks for your reply..I might have missed that one but am confident that with this board I will find plenty of others. Appreciate your and your members honest DD with their stocks. As for CLDX, I jumped into it for a small amount..
Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates.
"Seattle Genetics (Nasdaq: SGEN) now has 10 ADC collaborations with companies as small as Celldex Therapeutics (Nasdaq: CLDX)"
One of the main parts: Our deep product pipeline consists of products in varying stages of development, with lead candidate rindopepimut (CDX-110) currently undergoing evaluation in a Phase 2 clinical trial in newly diagnosed glioblastoma multiforme, one of the most aggressive forms of brain cancer.